CIENCIASMEDICASNEWS

sábado, 20 de diciembre de 2025

https://www.nih.gov/about-nih/nih-director/statements/roadmap-engaging-public-partners-clinical-research ROADMAP FOR ENGAGING THE PUBLIC AS PARTNERS IN CLINICAL RESEARCH https://osp.od.nih.gov/wp-content/uploads/2025/12/NExTRACs-ENGAGE-Report_FINAL.pdf At the National Institutes of Health (NIH), engendering trust and confidence in the research we support is one of our top priorities. Three things guide these efforts: engaging in open, honest dialogue, acting in transparency, and delivering on our commitment to advancing science and improving health. To help guide this work, the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) recently undertook a multi-year effort to provide the NIH with a roadmap for incorporating public voices in clinical research (see NExTRAC report) . Deliberations were informed by a team of multi-disciplinary experts and community conversations across the country , specifically asked to think about strategies for incorporating public voices at every stage of the clinical research process. https://partnersinresearch.nih.gov/members/ I am pleased to endorse these recommendations, which focus on: --providing a clear vision and framework for maximally involving patients and communities in clinical research; --ensuring that people and communities have meaningful input into the agenda and direction of research that is relevant and impactful for them; and --increasing transparency for how research participant data are utilized in moving the scientific enterprise forward. NIH is eager to begin implementing this roadmap, starting in 2026. First, NIH will work with the community to make the return of participant research results standard practice. Initial efforts will focus on returning summary-level research results, with the intent of augmenting practices that result in returning individual-level research results to research participants. Providing individuals with their research data so they can make their own healthcare decisions is one of my top priorities as NIH Director. NIH is also working towards harnessing the widespread adoption of electronic health records and other large scale electronic clinical information systems to accelerate biomedical research in ways not previously possible. In the spirit of transparency, NIH is establishing agency-wide principles to foster, promote, and guide the responsible conduct of research using clinical data. These principles serve as an initial transparent foundation for building trust with the public in how their data are respected and shared to drive improvements in health across the country. I want to thank the NExTRAC and the ENGAGE Working Group members for their keen insights and thoughtful deliberations. Their efforts will serve as a valuable tool toward improving the health of all Americans. Dr. Jay Bhattacharya NIH Director About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit . NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This Statement is available online at:

Studies on nano magnesium oxide modified acrylic resin in antibacterial coating application Tirthankar Jana* [1] , Tapan Kumar Dhar [1]

https://www.academia.edu/2997-2027/2/4/10.20935/AcadMatSci8044 The present study is related to the impact of nano magnesium oxide modified hybrid acrylic resin as a dual functional component in coating applications. Such nano magnesium oxide modified hybrid acrylic acts as a film former as well as antimicrobial agent. Nano magnesium oxide modification into acrylic resin was carried out through chemical modification with specially designed acrylic resin and confirmed by IR spectroscopic and SEM analysis. The effect of nano magnesium oxide modified hybrid acrylic resin was evaluated in water-based paint composition and compared against acrylic paint containing commercial biocides. The results revealed enhancement of coating properties like opacity (5%), whiteness (6%), gloss (7.5%) and antibacterial performance (more than 99% reduction of bacterial concentration) in magnesium oxide modified acrylic paint against unmodified ones and comparable with paint properties containing commercial biocides. The study shows that specially designed nano MgO modified acrylic resin can be used to make antibacterial coating without using commercial biocides.